Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
25 lessons
8mPeptidesIntermediate
July 2026 Peptide Research Snapshot: Retatrutide, BPC-157, MOTS-C, GHK-Cu, and Tesamorelin
The peptide space is loud. This snapshot cuts through the noise and focuses on the compounds that still have real biology behind them.
8mPeptidesIntermediate
MOTS-C and Human Mesenchymal Stromal Cells: The Tradeoff Nobody Wanted to Miss
MOTS-C may help metabolic signaling in human cells, but the same signal could come with a repair cost. That matters for anyone reading the longevity hype.
10mPeptidesIntermediate
July 2026 Peptide Research Signals: The 5 Compounds Worth Watching
The most useful peptide research is not the loudest. It is the stuff that changes the question from 'does it work?' to 'who does it help, for what outcome, and with what tradeoffs?'
9mPeptidesIntermediate
Therapeutic Peptides in Gerontology: What Healthy Aging Research Actually Shows
Healthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mPeptidesIntermediate
GLP-1s, Delayed Gastric Emptying, and Surgery: What the Perioperative Debate Means
GLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.
9mPeptidesIntermediate
GHK-Cu, Collagen, and Tissue Remodeling: What the Research Actually Suggests
GHK-Cu is more than a cosmetic peptide. The interesting signal is tissue remodeling, matrix repair, and how that may matter for skin, hair, and recovery.
9mPeptidesIntermediate
Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds
Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?
8mPeptidesIntermediate
MOTS-c and Cardiac Ischemia-Reperfusion: What the New Rat-Heart Study Shows
MOTS-c is showing up in cardiac stress research. A new rat-heart study points toward mitochondrial bioenergetics, mtDNA integrity, and post-ischemic recovery.
8mPeptidesIntermediate
MOTS-c and Inflammatory Lung Disease: What the New Research Suggests
MOTS-c is moving beyond generic energy claims. New research points toward mitochondrial stress response, lung inflammation, and cardiac reperfusion biology.
8mPeptidesIntermediate
GLP-1s and Biological Aging: What the New Semaglutide Study Shows
GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.
8mPeptidesIntermediate
MOTS-c and Soft Tissue Survival: What the New Autophagy Study Suggests
MOTS-c is being studied beyond energy and metabolism. New research points toward tissue-stress biology, lysosomal stability, and cell survival under ischemic pressure.
8mPeptidesIntermediate
GLP-1s and Breast Cancer Risk: What the New Signal Means
GLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
8mResearchAdvanced
Peptide Clinical Evidence in 2026: How to Separate Signal from Hype
Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mPeptidesIntermediate
MOTS-c and Arterial Stiffness: What the 2026 Pilot Study Shows
A new MOTS-c pilot study adds a vascular-health signal to the mitochondrial peptide conversation, but it should be read as biomarker research, not a protocol claim.
7mPeptidesIntermediate
Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means
Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.
8mPeptidesIntermediate
GHK-Cu vs Minoxidil: The Copper Peptide That Outperformed the #1 Hair Loss Treatment
Most people fighting hair loss default to minoxidil. But a 2022 clinical trial showed a 0.5% GHK-Cu serum increased hair count by 22% over 16 weeks — beating 3% minoxidil. And GHK-Cu doesn't just grow hair. It works at the genomic level.
9mPeptidesIntermediate
GHK-Cu and Cognitive Aging: New Research on the Copper Peptide's Brain Benefits
GHK-Cu has long been known for its skin and healing benefits. A fresh April 2026 preprint adds a surprising new dimension — cognitive aging reversal in mouse models via BDNF upregulation and neuroinflammation suppression.
10mPolicyAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
After years of regulatory uncertainty, BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding access in 2026. Here's what the FDA reclassification means for peptide researchers.
14mPeptidesAdvanced
Peptides for Longevity: The Emerging Science Behind Age-Reversal Compounds
The peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.
10mPeptidesIntermediate
Latest Peptide Research Breakthroughs: What's Coming in 2026
The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.
10mPeptidesIntermediate
Peptide Research Breakthroughs in 2026: What Clinical Trials Show
2026 marks a pivotal year for peptide research. Here's what the latest clinical data reveals about the most promising peptide candidates and their real-world applications.
10mResearchAdvanced
How to Read Peptide Research: Understanding Studies and Claims
Develop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.